Abcodia company

Abcodia is a clinical stage company engaged in the commercial development of novel, validated tests for the early detection of cancer. The company’s first product is the ROCA test for the early detection of ovarian cancer, and it is also expanding its pipeline of early detection technologies for lung, colorectal and pancreatic cancer. Abcodia’s offerings are based on expertise in measuring and modeling dynamic changes over time of serum-based biomarkers before cancer is clinically diagnosed.It maintains exclusive commercial access to a biobank of 5 million samples donated from 200,000 individuals over a 10-year period and has its own CLIA-certified laboratory. Abcodia holds strategic collaborations with leading global organizations including Cancer Research UK, University College London and other academic and industry partners.
Technology: P4 Medicine
Industry: Regenerative Medicine
Headquarters: London, England, United Kingdom
Founded Date: 2010
Employees Number: 1-10
Funding Status: Early Stage Venture

Visit Website
Register and Claim Ownership